Fukuyama muscular dystrophy (FCMD; MIM253800), one of the most common autosomal recessive disorders in Japan, was the first human disease found to result from ancestral insertion of a SINE-VNTR-Alu (SVA) retrotransposon into a causative gene1, 2, 3. In FCMD, the SVA insertion occurs in the 3′ untranslated region (UTR) of the fukutin gene. The pathogenic mechanism for FCMD is unknown, and no effective clinical treatments exist. Here we show that aberrant messenger RNA (mRNA) splicing, induced by SVA exon-trapping, underlies the molecular pathogenesis of FCMD. Quantitative mRNA analysis pinpointed a region that was missing from transcripts in patients with FCMD. This region spans part of the 3′ end of the fukutin coding region, a proximal part of the 3′ UTR and the SVA insertion. Correspondingly, fukutin mRNA transcripts in patients with FCMD and SVA knock-in model mice were shorter than the expected length. Sequence analysis revealed an abnormal splicing event, provoked by a strong acceptor site in SVA and a rare alternative donor site in fukutin exon 10. The resulting product truncates the fukutin carboxy (C) terminus and adds 129 amino acids encoded by the SVA. Introduction of antisense oligonucleotides (AONs) targeting the splice acceptor, the predicted exonic splicing enhancer and the intronic splicing enhancer prevented pathogenic exon-trapping by SVA in cells of patients with FCMD and model mice, rescuing normal fukutin mRNA expression and protein production. AON treatment also restored fukutin functions, including O-glycosylation of α-dystroglycan (α-DG) and laminin binding by α-DG. Moreover, we observe exon-trapping in other SVA insertions associated with disease (hypercholesterolemia4, neutral lipid storage disease5) and human-specific SVA insertion in a novel gene. Thus, although splicing into SVA is known6, 7, 8, we have discovered in human disease a role for SVA-mediated exon-trapping and demonstrated the promise of splicing modulation therapy as the first radical clinical treatment for FCMD and other SVA-mediated diseases.
At a glance
- Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31–33. Nature Genet. 5, 283–286 (1993) et al.
- An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394, 388–392 (1998) et al.
- Founder SVA retrotransposal insertion in Fukuyama-type congenital muscular dystrophy and its origin in Japanese and Northeast Asian populations. Am. J. Med. Genet. A. 138, 344–348 (2005) et al.
- Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum. Mol. Genet. 11, 3019–3030 (2002) et al.
- Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. Neuromuscul. Disord. 20, 397–402 (2010) et al.
- Exon-trapping mediated by the human retrotransposon SVA. Genome Res. 19, 1983–1991 (2009) et al.
- 5′-Transducing SVA retrotransposon groups spread efficiently throughout the human genome. Genome Res. 19, 1992–2008 (2009) et al.
- Novel family of human transposable elements formed due to fusion of the first exon of gene MAST2 with retrotransposon SVA. Biochemistry (Mosc.) 74, 1393–1399 (2009) &
- Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418, 417–422 (2002) et al.
- Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell Sci. 119, 199–207 (2006) &
- Retroposed copies of the HMG genes: a window to genome dynamics. Genome Res. 13, 800–812 (2003) et al.
- SVA elements are nonautonomous retrotransposons that cause disease in humans. Am. J. Hum. Genet. 73, 1444–1451 (2003) et al.
- Natural genetic variation caused by transposable elements in humans. Genetics 168, 933–951 (2004) et al.
- SVA elements: a hominid-specific retroposon family. J. Mol. Biol. 354, 994–1007 (2005) et al.
- Retrotransposition of marked SVA elements by human L1s in cultured cells. Hum. Mol. Genet. 20, 3386–3400 (2011) et al.
- Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum. Mol. Genet. 18, 621–631 (2009) et al.
- SVA retrotransposons: evolution and genetic instability. Semin. Cancer Biol. 20, 234–245 (2010) &
- Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol. Ther. 17, 864–871 (2009) et al.
- LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nature Med. 10, 696–703 (2004) et al.
- Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001) et al.
- Mobile elements: drivers of genome evolution. Science 303, 1626–1632 (2004)
- The impact of retrotransposons on human genome evolution. Nature Rev. Genet. 10, 691–703 (2009) &
- A novel mobile element inserted in the α spectrin gene: spectrin dayton. A truncated α spectrin associated with hereditary elliptocytosis. J. Clin. Invest. 94, 643–648 (1994) et al.
- Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions. Clin. Immunol. 90, 28–37 (1999) et al.
- Molecular characterization of germline NF2 gene rearrangements. Genomics 65, 62–66 (2000) et al.
- Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am. J. Hum. Genet. 80, 393–406 (2007) et al.
- Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25, 1114–1120 (2007) et al.
- Vitravene—another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 8, vii–viii. (1998) et al.
- Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Med. 9, 1009–1014 (2003) et al.
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Med. 12, 175–177 (2006) et al.
- Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667–676 (2009) et al.
- Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum. Mol. Genet. 12, 1449–1459 (2003) et al.
- Repbase Update: a database and an electronic journal of repetitive elements. Trends Genet. 9, 418–420 (2000)
- Supplementary Information (3.4M)
This file contains supplementary Figures 1-13 with legends and Supplementary Table 1.